{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:59:20Z","timestamp":1790495960722,"version":"4.1.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T00:00:00Z","timestamp":1361232000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1038\/nrrheum.2013.7","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T09:52:06Z","timestamp":1361267526000},"page":"173-182","source":"Crossref","is-referenced-by-count":115,"title":["Back to the future: oral targeted therapy for RA and other autoimmune diseases"],"prefix":"10.1038","volume":"9","author":[{"given":"John J.","family":"O'Shea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,19]]},"reference":[{"key":"BFnrrheum20137_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","volume":"16","author":"WJ Leonard","year":"1998","unstructured":"Leonard, W. J. & O'Shea, J. J. JAKs and STATs: biological implications. Ann. Rev. Immunol. 16, 293\u2013322 (1998).","journal-title":"Ann. Rev. Immunol."},{"key":"BFnrrheum20137_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O'Shea","year":"2013","unstructured":"O'Shea, J. J., Holland, S. M. & Staudt, L. M. JAKs and STATs in immunity, immunodeficiency and cancer. N. Engl. J. Med. 368, 161\u2013170 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20137_CR3","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi, K.  et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186, 4234\u20134243 (2011).","journal-title":"J. Immunol."},{"key":"BFnrrheum20137_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman, M. W.  et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127\u2013132 (2008).","journal-title":"Nat. Biotechnol."},{"key":"BFnrrheum20137_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1126\/science.1087061","volume":"302","author":"PS Changelian","year":"2003","unstructured":"Changelian, P. S.  et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875\u2013878 (2003).","journal-title":"Science"},{"key":"BFnrrheum20137_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann, R.  et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495\u2013507 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20137_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven, R. F.  et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508\u2013519 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20137_CR8","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer, J. M.  et al. A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum. 64, 970\u2013981 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20137_CR9","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer, J. M.  et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60, 1895\u20131905 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20137_CR10","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/acr.20494","volume":"63","author":"Y Tanaka","year":"2011","unstructured":"Tanaka, Y., Suzuki, M., Nakamura, H., Toyoizumi, S. & Zwillich, S. H. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. (Hoboken) 63, 1150\u20131158 (2011).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"BFnrrheum20137_CR11","doi-asserted-by":"publisher","unstructured":"Burmester, G. R.  et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet \n                    http:\/\/dx.doi.org\/10.1016\/S0140\u20136736(12)61424-X\n                    \n                  .","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"BFnrrheum20137_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn, W. J.  et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616\u2013624 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum20137_CR13","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","volume":"167","author":"KA Papp","year":"2012","unstructured":"Papp, K. A.  et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br. J. Dermatol. 167, 668\u2013677 (2012).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum20137_CR14","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","volume":"12","author":"F Vincenti","year":"2012","unstructured":"Vincenti, F.  et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am. J. Transplant. 12, 2446\u20132456 (2012).","journal-title":"Am. J. Transplant."},{"key":"BFnrrheum20137_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/art.33383","volume":"64","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann, R.  et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 64, 617\u2013629 (2012).","journal-title":"Arthritis Rheum."},{"issue":"Suppl.","key":"BFnrrheum20137_CR16","first-page":"S546","volume":"64","author":"D van der Heijde","year":"2012","unstructured":"van der Heijde, D.  et al. Tofacitinib, an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: year 2 efficacy and safety results from a 24-month phase 3 study [abstract 1277]. Arthritis Rheum. 64 (Suppl.), S546 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20137_CR17","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","volume":"119","author":"A Tefferi","year":"2012","unstructured":"Tefferi, A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 119, 2721\u20132730 (2012).","journal-title":"Blood"},{"key":"BFnrrheum20137_CR18","first-page":"111","volume":"10","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek, S. Ruxolitinib: the first agent approved for myelofibrosis. Clin. Adv. Hematol. Oncol. 10, 111\u2013113 (2012).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"BFnrrheum20137_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison, C.  et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787\u2013798 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl.","key":"BFnrrheum20137_CR20","first-page":"S911","volume":"62","author":"MW Greenwald","year":"2010","unstructured":"Greenwald, M. W.  et al. A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis [abstract 2172]. Arthritis Rheum. 62 (Suppl.), S911 (2010).","journal-title":"Arthritis Rheum."},{"issue":"Suppl.","key":"BFnrrheum20137_CR21","first-page":"S214","volume":"64","author":"JS Smolen","year":"2012","unstructured":"Smolen, J. S.  et al. 12- and 24-week patient-reported outcomes from a phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1\/Janus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis [abstract 490]. Arthritis Rheum. 64 (Suppl.), S214 (2012).","journal-title":"Arthritis Rheum."},{"issue":"Suppl.","key":"BFnrrheum20137_CR22","first-page":"S1049","volume":"64","author":"MC Genovese","year":"2012","unstructured":"Genovese, M. C.  et al. 24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1\/Januse kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis [abstract 2487]. Arthritis Rheum. 64 (Suppl.), S1049\u2013S1050 (2012).","journal-title":"Arthritis Rheum."},{"issue":"Suppl.","key":"BFnrrheum20137_CR23","first-page":"S1050","volume":"64","author":"CG Peterfy","year":"2012","unstructured":"Peterfy, C. G.  et al. Magnetic resonance imaging substudy in a phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1\/Janus kinase 2 inhibitor, in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis [abstract 2488]. Arthritis Rheum. 64 (Suppl.), S1050\u2013S1051 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20137_CR24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","volume":"36","author":"JJ O'Shea","year":"2012","unstructured":"O'Shea, J. J. & Plenge, R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36, 542\u2013550 (2012).","journal-title":"Immunity"},{"key":"BFnrrheum20137_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1189\/jlb.0504282","volume":"76","author":"M Conklyn","year":"2004","unstructured":"Conklyn, M., Andresen, C., Changelian, P. & Kudlacz, E. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J. Leukoc. Biol. 76, 1248\u20131255 (2004).","journal-title":"J. Leukoc. Biol."},{"key":"BFnrrheum20137_CR26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/01.tp.0000177643.05739.cd","volume":"80","author":"R Paniagua","year":"2005","unstructured":"Paniagua, R.  et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 80, 1283\u20131292 (2005).","journal-title":"Transplantation"},{"key":"BFnrrheum20137_CR27","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/art.34329","volume":"64","author":"K Maeshima","year":"2012","unstructured":"Maeshima, K.  et al. A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN-\u03b3 and IL-17 production by human CD4+ T cells. Arthritis Rheum. 64, 1790\u20131798 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20137_CR28","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1002\/art.34649","volume":"64","author":"TP Labranche","year":"2012","unstructured":"Labranche, T. P.  et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 64, 3531\u20133542 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20137_CR29","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1126\/science.270.5237.794","volume":"270","author":"DC Thomis","year":"1995","unstructured":"Thomis, D. C., Gurniak, C. B., Tivol, E., Sharpe, A. H. & Berg, L. J. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking JAK3. Science 270, 794\u2013797 (1995).","journal-title":"Science"},{"key":"BFnrrheum20137_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/377065a0","volume":"377","author":"P Macchi","year":"1995","unstructured":"Macchi, P.  et al. Mutations of JAK-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65\u201368 (1995).","journal-title":"Nature"},{"key":"BFnrrheum20137_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1126\/science.270.5237.797","volume":"270","author":"SM Russell","year":"1995","unstructured":"Russell, S. M.  et al. Mutation of JAK3 in a patient with SCID: essential role of JAK3 in lymphoid development. Science 270, 797\u2013800 (1995).","journal-title":"Science"},{"key":"BFnrrheum20137_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1126\/science.270.5237.800","volume":"270","author":"T Nosaka","year":"1995","unstructured":"Nosaka, T.  et al. Defective lymphoid development in mice lacking Jak3. Science 270, 800\u2013802 (1995).","journal-title":"Science"},{"key":"BFnrrheum20137_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","volume":"93","author":"SJ Rodig","year":"1998","unstructured":"Rodig, S. J.  et al. Disruption of the JAK1 gene demonstrates obligatory and nonredundant roles of the JAKs in cytokine-induced biologic responses. Cell 93, 373\u2013383 (1998).","journal-title":"Cell"},{"key":"BFnrrheum20137_CR34","unstructured":"US National Library of Medicine. A study to evaluate both the efficacy and safety profile of CP-690,550 in patients with moderately to severely active ulcerative colitis (OCTAVE). ClinicalTrials.gov\n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum20137_CR35","unstructured":"US National Library of Medicine. A study evaluating the efficacy and safety of CP-690,550 in patients with moderate to severe ulcerative colitis (OCTAVE). ClinicalTrials.gov\n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum20137_CR36","unstructured":"US National Library of Medicine. A study of oral CP-690550 as a maintenance therapy for ulcerative colitis (OCTAVE). ClinicalTrials.gov\n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum20137_CR37","unstructured":"US National Library of Medicine. Study of the mechanism of action of CP-690,550 in the skin of subjects with moderate to severe chronic plaque psoriasis. ClinicalTrials.gov\n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum20137_CR38","unstructured":"US National Library of Medicine. Pharmacokinetics of CP-690,550 in pediatric patients with juvenile idiopathic arthritis (JIA). ClinicalTrials.gov\n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum20137_CR39","unstructured":"US National Library of Medicine. Long-term safety study of CP-690,550 in patients with juvenile idiopathic arthritis. ClinicalTrials.gov\n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrrheum20137_CR40","unstructured":"US National Library of Medicine. A one-year study to evaluate the effects and safety of CP-690,550 in patients with moderate to severe chronic plaque psoriasis. ClinicalTrials.gov\n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum20137_CR41","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/ar3329","volume":"13","author":"KL Stump","year":"2011","unstructured":"Stump, K. L.  et al. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res. Ther. 13, R68 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum20137_CR42","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1177\/0961203311409963","volume":"20","author":"M Kawasaki","year":"2011","unstructured":"Kawasaki, M.  et al. Possible role of the JAK\/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus. Lupus 20, 1231\u20131239 (2011).","journal-title":"Lupus"},{"key":"BFnrrheum20137_CR43","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1177\/0961203310367660","volume":"19","author":"S Wang","year":"2010","unstructured":"Wang, S.  et al. Jak\/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL\/lpr mice. Lupus 19, 1171\u20131180 (2010).","journal-title":"Lupus"},{"key":"BFnrrheum20137_CR44","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejphar.2007.12.024","volume":"582","author":"E Kudlacz","year":"2008","unstructured":"Kudlacz, E., Conklyn, M., Andresen, C., Whitney-Pickett, C. & Changelian, P. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur. J. Pharmacol. 582, 154\u2013161 (2008).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrrheum20137_CR45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/BOR.0b013e32835190ef","volume":"24","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann, R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr. Opin. Rheumatol. 24, 335\u2013341 (2012).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum20137_CR46","unstructured":"US National Library of Medicine. A 12-week study of 4 doses of VX-509 in subjects with active rheumatoid arthritis. ClinicalTrials.gov\n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum20137_CR47","unstructured":"US National Library of Medicine. A magnetic resonance imaging study and arthroscopic biopsy substudy in subjects with active rheumatoid arthritis receiving VX-509, an oral JAK3 inhibitor. ClinicalTrials.gov\n                    [online]\n                    \n                  , (2013)."},{"issue":"Suppl.","key":"BFnrrheum20137_CR48","first-page":"S1051","volume":"64","author":"F Vanhoutte","year":"2012","unstructured":"Vanhoutte, F., Mazur, M., Van der Aa, A., Wigerinck, P. & van 't Klooster, G. Selective JAK1 inhibition in the treatment of rheumatoid arthritis: proof of concept with GLPG0634 [abstract 2489]. Arthritis Rheum. 64 (Suppl.), S1051 (2012).","journal-title":"Arthritis Rheum."},{"issue":"Suppl.","key":"BFnrrheum20137_CR49","first-page":"S573","volume":"64","author":"F Namour","year":"2012","unstructured":"Namour, F.  et al. Once daily high dose regimens of GLPG0634 in healthy volunteers are safe and provide continuous inhibition of JAK1 but not JAK2 [abstract 1331]. Arthritis Rheum. 64 (Suppl.), S573 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20137_CR50","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev.immunol.20.092601.111357","volume":"20","author":"LE Samelson","year":"2002","unstructured":"Samelson, L. E. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu. Rev. Immunol. 20, 371\u2013394 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum20137_CR51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1600-065X.1998.tb01238.x","volume":"165","author":"DH Chu","year":"1998","unstructured":"Chu, D. H., Morita, C. T. & Weiss, A. The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol. Rev. 165, 167\u2013180 (1998).","journal-title":"Immunol. Rev."},{"key":"BFnrrheum20137_CR52","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","volume":"27","author":"JE Smith-Garvin","year":"2009","unstructured":"Smith-Garvin, J. E., Koretzky, G. A. & Jordan, M. S. T cell activation. Annu. Rev. Immunol. 27, 591\u2013619 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum20137_CR53","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1146\/annurev.immunol.17.1.555","volume":"17","author":"T Kurosaki","year":"1999","unstructured":"Kurosaki, T. Genetic analysis of B cell antigen receptor signaling. Annu. Rev. Immunol. 17, 555\u2013592 (1999).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum20137_CR54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1600-065X.2008.00742.x","volume":"228","author":"AM Gilfillan","year":"2009","unstructured":"Gilfillan, A. M. & Rivera, J. The tyrosine kinase network regulating mast cell activation. Immunol. Rev. 228, 149\u2013169 (2009).","journal-title":"Immunol. Rev."},{"key":"BFnrrheum20137_CR55","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/0952-7915(92)90072-M","volume":"4","author":"AC Chan","year":"1992","unstructured":"Chan, A. C., Irving, B. A. & Weiss, A. New insights into T-cell antigen receptor structure and signal transduction. Curr. Opin. Immunol. 4, 246\u2013251 (1992).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrrheum20137_CR56","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1126\/science.8202713","volume":"264","author":"AC Chan","year":"1994","unstructured":"Chan, A. C.  et al. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science 264, 1599\u20131601 (1994).","journal-title":"Science"},{"key":"BFnrrheum20137_CR57","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev.iy.12.040194.002325","volume":"12","author":"JC Cambier","year":"1994","unstructured":"Cambier, J. C., Pleiman, C. M. & Clark, M. R. Signal transduction by the B cell antigen receptor and its coreceptors. Annu. Rev. Immunol. 12, 457\u2013486, (1994).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum20137_CR58","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","volume":"10","author":"A M\u00f3csai","year":"2010","unstructured":"M\u00f3csai, A., Ruland, J. & Tybulewicz, V. L. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10, 387\u2013402 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum20137_CR59","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/378298a0","volume":"378","author":"M Turner","year":"1995","unstructured":"Turner, M.  et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 378, 298\u2013302 (1995).","journal-title":"Nature"},{"key":"BFnrrheum20137_CR60","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1126\/science.1079477","volume":"299","author":"F Abtahian","year":"2003","unstructured":"Abtahian, F.  et al. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 299, 247\u2013251 (2003).","journal-title":"Science"},{"key":"BFnrrheum20137_CR61","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.clim.2007.03.543","volume":"124","author":"PR Pine","year":"2007","unstructured":"Pine, P. R.  et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin. Immunol. 124, 244\u2013257 (2007).","journal-title":"Clin. Immunol."},{"key":"BFnrrheum20137_CR62","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1002\/art.23992","volume":"58","author":"ME Weinblatt","year":"2008","unstructured":"Weinblatt, M. E.  et al. Treatment of rheumatoid arthritis with a SYK kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309\u20133318 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20137_CR63","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/art.30114","volume":"63","author":"MC Genovese","year":"2011","unstructured":"Genovese, M. C.  et al. An oral SYK kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 63, 337\u2013345 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20137_CR64","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.clim.2011.12.012","volume":"142","author":"PM Barr","year":"2012","unstructured":"Barr, P. M.  et al. Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. Clin. Immunol. 142, 237\u2013242 (2012).","journal-title":"Clin. Immunol."},{"key":"BFnrrheum20137_CR65","unstructured":"US National Library of Medicine. Evaluation of long-term safety and effectiveness of fostamatinib in the treatment of rheumatoid arthritis (RA) (OSKIRA-X). ClinicalTrials.gov\n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrrheum20137_CR66","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/art.23428","volume":"58","author":"FR Bahjat","year":"2008","unstructured":"Bahjat, F. R.  et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 58, 1433\u20131444 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20137_CR67","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/art.27534","volume":"62","author":"GM Deng","year":"2010","unstructured":"Deng, G. M., Liu, L., Bahjat, F. R., Pine, P. R. & Tsokos, G. C. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum. 62, 2086\u20132092 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum20137_CR68","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg, J. W.  et al. Inhibition of SYK with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578\u20132585 (2010).","journal-title":"Blood"},{"key":"BFnrrheum20137_CR69","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/j.1742-4658.2011.08072.x","volume":"278","author":"J Gomez-Rodriguez","year":"2011","unstructured":"Gomez-Rodriguez, J., Kraus, Z. J. & Schwartzberg, P. L. Tec family kinases Itk and Rlk\/Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates. FEBS J. 278, 1980\u20131989 (2011).","journal-title":"FEBS J."},{"key":"BFnrrheum20137_CR70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1600-065X.1994.tb00849.x","volume":"138","author":"DJ Rawlings","year":"1994","unstructured":"Rawlings, D. J. & Witte, O. N. Bruton's tyrosine kinase is a key regulator in B-cell development. Immunol. Rev. 138, 105\u2013119 (1994).","journal-title":"Immunol. Rev."},{"key":"BFnrrheum20137_CR71","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1126\/science.8332900","volume":"261","author":"JD Thomas","year":"1993","unstructured":"Thomas, J. D.  et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 261, 355\u2013358 (1993).","journal-title":"Science"},{"key":"BFnrrheum20137_CR72","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/08830185.2012.670334","volume":"31","author":"NJ Horwood","year":"2012","unstructured":"Horwood, N. J., Urbaniak, A. M. & Danks, L. Tec family kinases in inflammation and disease. Int. Rev. Immunol. 31, 87\u2013103 (2012).","journal-title":"Int. Rev. Immunol."},{"key":"BFnrrheum20137_CR73","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1111\/j.1742-4658.2011.08073.x","volume":"278","author":"W Ellmeier","year":"2011","unstructured":"Ellmeier, W., Abramova, A. & Schebesta, A. Tec family kinases: regulation of Fc\u03b5RI-mediated mast-cell activation. FEBS J. 278, 1990\u20132000 (2011).","journal-title":"FEBS J."},{"key":"BFnrrheum20137_CR74","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/ar3400","volume":"13","author":"BY Chang","year":"2011","unstructured":"Chang, B. Y.  et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther. 13, R115 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum20137_CR75","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg, L. A.  et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075\u201313080 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum20137_CR76","first-page":"313","volume":"3","author":"A Weiss","year":"1991","unstructured":"Weiss, A., Irving, B. A., Tan, L. K. & Koretzky, G. A. Signal transduction by the T cell antigen receptor. Semin. Immunol. 3, 313\u2013324 (1991).","journal-title":"Semin. Immunol."},{"key":"BFnrrheum20137_CR77","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0065-2776(01)79003-7","volume":"79","author":"D Yablonski","year":"2001","unstructured":"Yablonski, D. & Weiss, A. Mechanisms of signaling by the hematopoietic-specific adaptor proteins, SLP-76 and LAT and their B cell counterpart, BLNK\/SLP-65. Adv. Immunol. 79, 93\u2013128 (2001).","journal-title":"Adv. Immunol."},{"key":"BFnrrheum20137_CR78","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1146\/annurev.immunol.19.1.497","volume":"19","author":"RS Lewis","year":"2001","unstructured":"Lewis, R. S. Calcium signaling mechanisms in T lymphocytes. Annu. Rev. Immunol. 19, 497\u2013521 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum20137_CR79","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1034\/j.1600-065X.2003.00027.x","volume":"192","author":"A Altman","year":"2003","unstructured":"Altman, A. & Villalba, M. Protein kinase C-\u03b8 (PKC\u03b8): it's all about location, location, location. Immunol. Rev. 192, 53\u201363 (2003).","journal-title":"Immunol. Rev."},{"key":"BFnrrheum20137_CR80","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1586\/eci.12.8","volume":"8","author":"A Altman","year":"2012","unstructured":"Altman, A. & Kong, K. F. PKC\u03b8: a new target for selective immunosuppression. Expert Rev. Clin. Immunol. 8, 205\u2013208 (2012).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"BFnrrheum20137_CR81","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/TP.0b013e318265c4d8","volume":"94","author":"TF Fuller","year":"2012","unstructured":"Fuller, T. F.  et al. Protein kinase C inhibition ameliorates posttransplantation preservation injury in rat renal transplants. Transplantation 94, 679\u2013686 (2012).","journal-title":"Transplantation"},{"key":"BFnrrheum20137_CR82","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1158\/1535-7163.MCT-12-0121","volume":"11","author":"X Wu","year":"2012","unstructured":"Wu, X., Li, J., Zhu, M., Fletcher, J. A. & Hodi, F. S. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC\/Erk1\/2 and PKC\/NF-\u03baB pathways. Mol. Cancer Ther. 11, 1905\u20131914 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrrheum20137_CR83","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/369327a0","volume":"369","author":"F Pag\u00e8s","year":"1994","unstructured":"Pag\u00e8s, F.  et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 369, 327\u2013329 (1994).","journal-title":"Nature"},{"key":"BFnrrheum20137_CR84","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1084\/jem.20020307","volume":"196","author":"RG Jones","year":"2002","unstructured":"Jones, R. G.  et al. CD28-dependent activation of protein kinase B\/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J. Exp. Med. 196, 335\u2013348 (2002).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum20137_CR85","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1021\/cr000091i","volume":"101","author":"NR Leslie","year":"2001","unstructured":"Leslie, N. R., Biondi, R. M. & Alessi, D. R. Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem. Rev. 101, 2365\u20132380 (2001).","journal-title":"Chem. Rev."},{"key":"BFnrrheum20137_CR86","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1073\/pnas.042707999","volume":"99","author":"AL Edinger","year":"2002","unstructured":"Edinger, A. L. & Thompson, C. B. Antigen-presenting cells control T cell proliferation by regulating amino acid availability. Proc. Natl Acad. Sci. USA 99, 1107\u20131109 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum20137_CR87","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1074-7613(02)00323-0","volume":"16","author":"KA Frauwirth","year":"2002","unstructured":"Frauwirth, K. A.  et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769\u2013777 (2002).","journal-title":"Immunity"},{"key":"BFnrrheum20137_CR88","doi-asserted-by":"publisher","first-page":"6869","DOI":"10.4049\/jimmunol.167.12.6869","volume":"167","author":"JC Rathmell","year":"2001","unstructured":"Rathmell, J. C., Farkash, E. A., Gao, W. & Thompson, C. B. IL-7 enhances the survival and maintains the size of naive T cells. J. Immunol. 167, 6869\u20136876 (2001).","journal-title":"J. Immunol."},{"key":"BFnrrheum20137_CR89","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1073\/pnas.96.8.4240","volume":"96","author":"LC Cantley","year":"1999","unstructured":"Cantley, L. C. & Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase\/AKT pathway. Proc. Natl Acad. Sci. USA 96, 4240\u20134245 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum20137_CR90","doi-asserted-by":"publisher","first-page":"32662","DOI":"10.1074\/jbc.274.46.32662","volume":"274","author":"LO Beitz","year":"1999","unstructured":"Beitz, L. O., Fruman, D. A., Kurosaki, T., Cantley, L. C. & Scharenberg, A. M. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J. Biol. Chem. 274, 32662\u201332666 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum20137_CR91","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1091\/mbc.01-12-0584","volume":"13","author":"AL Edinger","year":"2002","unstructured":"Edinger, A. L. & Thompson, C. B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13, 2276\u20132288 (2002).","journal-title":"Mol. Biol. Cell"},{"key":"BFnrrheum20137_CR92","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ki.1996.28","volume":"49","author":"MG Murgia","year":"1996","unstructured":"Murgia, M. G., Jordan, S. & Kahan, B. D. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine\u2013prednisone-treated renal transplant patients. Kidney Int. 49, 209\u2013216 (1996).","journal-title":"Kidney Int."},{"issue":"Suppl. 2","key":"BFnrrheum20137_CR93","first-page":"S46","volume":"252","author":"L Kappos","year":"2005","unstructured":"Kappos, L.  et al. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled clinical trial [abstract]. J. Neurol. 252 (Suppl. 2), S46 (2005).","journal-title":"J. Neurol."},{"key":"BFnrrheum20137_CR94","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev.immunol.20.091301.131133","volume":"20","author":"C Dong","year":"2002","unstructured":"Dong, C., Davis, R. J. & Flavell, R. A. MAP kinases in the immune response. Annu. Rev. Immunol. 20, 55\u201372 (2002).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum20137_CR95","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0952-7915(00)00224-7","volume":"13","author":"M Rincon","year":"2001","unstructured":"Rincon, M. MAP-kinase signaling pathways in T cells. Curr. Opin. Immunol. 13, 339\u2013345 (2001).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrrheum20137_CR96","doi-asserted-by":"publisher","first-page":"451","DOI":"10.12968\/hmed.2010.71.8.77669","volume":"71","author":"DH Josephs","year":"2010","unstructured":"Josephs, D. H. & Ross, P. J. Sorafenib in hepatocellular carcinoma. Br. J. Hosp. Med. (Lond.) 71, 451\u2013456 (2010).","journal-title":"Br. J. Hosp. Med. (Lond.)"},{"key":"BFnrrheum20137_CR97","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1200\/JCO.2006.08.4608","volume":"24","author":"R Govindarajan","year":"2006","unstructured":"Govindarajan, R., Adusumilli, J., Baxter, D. L., El-Khoueiry, A. & Harik, S. I. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43\u20139006. J. Clin. Oncol. 24, e48 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum20137_CR98","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s004150050360","volume":"246","author":"JM Gijtenbeek","year":"1999","unstructured":"Gijtenbeek, J. M., van den Bent, M. J. & Vecht, C. J. Cyclosporine neurotoxicity: a review. J. Neurol. 246, 339\u2013346 (1999).","journal-title":"J. Neurol."},{"key":"BFnrrheum20137_CR99","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00210-006-0117-7","volume":"374","author":"M Ohori","year":"2007","unstructured":"Ohori, M., Takeuchi, M., Maruki, R., Nakajima, H. & Miyake, H. FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiedebergs Arch. Pharmacol. 374, 311\u2013316 (2007).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"BFnrrheum20137_CR100","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/0092-8674(94)90056-6","volume":"77","author":"B Su","year":"1994","unstructured":"Su, B.  et al. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77, 727\u2013736 (1994).","journal-title":"Cell"},{"key":"BFnrrheum20137_CR101","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1126\/science.282.5396.2092","volume":"282","author":"C Dong","year":"1998","unstructured":"Dong, C.  et al. Defective T cell differentiation in the absence of Jnk1. Science 282, 2092\u20132095 (1998).","journal-title":"Science"},{"key":"BFnrrheum20137_CR102","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1074-7613(00)80640-8","volume":"9","author":"DD Yang","year":"1998","unstructured":"Yang, D. D.  et al. Differentiation of CD4+ T cells to TH1 cells requires MAP kinase JNK2. Immunity 9, 575\u2013585 (1998).","journal-title":"Immunity"},{"key":"BFnrrheum20137_CR103","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1084\/jem.20011481","volume":"195","author":"N Arbour","year":"2002","unstructured":"Arbour, N.  et al. c-Jun NH2-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8+ T cell-mediated antiviral immunity. J. Exp. Med. 195, 801\u2013810 (2002).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum20137_CR104","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1084\/jem.20011508","volume":"195","author":"D Conze","year":"2002","unstructured":"Conze, D.  et al. c-Jun NH2-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8+ T cell activation. J. Exp. Med. 195, 811\u2013823 (2002).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum20137_CR105","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0955-0674(98)80143-9","volume":"10","author":"YT Ip","year":"1998","unstructured":"Ip, Y. T. & Davis, R. J. Signal transduction by the c-Jun N-terminal kinase (JNK)\u2014from inflammation to development. Curr. Opin. Cell Biol. 10, 205\u2013219 (1998).","journal-title":"Curr. Opin. Cell Biol."},{"key":"BFnrrheum20137_CR106","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.1128\/MCB.17.11.6274","volume":"17","author":"JL Swantek","year":"1997","unstructured":"Swantek, J. L., Cobb, M. H. & Geppert, T. D. Jun N-terminal kinase\/stress-activated protein kinase (JNK\/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor \u03b1 (TNF-\u03b1) translation: glucocorticoids inhibit TNF-\u03b1 translation by blocking JNK\/SAPK. Mol. Cell. Biol. 17, 6274\u20136282 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrrheum20137_CR107","doi-asserted-by":"publisher","first-page":"6358","DOI":"10.1073\/pnas.94.12.6358","volume":"94","author":"T Ishizuka","year":"1997","unstructured":"Ishizuka, T.  et al. Mast cell tumor necrosis factor \u03b1 production is regulated by MEK kinases. Proc. Natl Acad. Sci. USA 94, 6358\u20136363 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum20137_CR108","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nrd1132","volume":"2","author":"AM Manning","year":"2003","unstructured":"Manning, A. M. & Davis, R. J. Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discov. 2, 554\u2013565 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrrheum20137_CR109","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/372739a0","volume":"372","author":"JC Lee","year":"1994","unstructured":"Lee, J. C.  et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739\u2013746 (1994).","journal-title":"Nature"},{"key":"BFnrrheum20137_CR110","first-page":"421","volume":"8","author":"C Dominguez","year":"2005","unstructured":"Dominguez, C., Powers, D. A. & Tamayo, N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Discov. Devel. 8, 421\u2013430 (2005).","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"BFnrrheum20137_CR111","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1016\/j.bmcl.2011.05.091","volume":"21","author":"AJ Dyckman","year":"2011","unstructured":"Dyckman, A. J.  et al. Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38\u03b1 MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 21, 4633\u20134637 (2011).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnrrheum20137_CR112","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/BOR.0b013e3283378e6f","volume":"22","author":"S Cohen","year":"2010","unstructured":"Cohen, S. & Fleischmann, R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr. Opin. Rheumatol. 22, 330\u2013335 (2010).","journal-title":"Curr. Opin. Rheumatol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:33:41Z","timestamp":1684470821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2013.7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,19]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["BFnrrheum20137"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2013.7","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,19]]}}}